Initial Treatment of Macular Oedema Due to Central Retinal Vein Occlusion—which Anti-Vegf Agent to Choose?

Eye - United Kingdom
doi 10.1038/s41433-019-0706-6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Intravitreal Bevacizumab for the Treatment of Macular Oedema Secondary to Branch Retinal Vein Occlusion

British Journal of Ophthalmology
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2008English

Intravitreal Triamcinolone Acetonide vs Bevacizumab for Treatment of Macular Oedema Secondary to Branch Retinal Vein Occlusion

Eye
MedicineArtsSensory SystemsOphthalmologyHumanities
2009English

Costs Associated With the Management and Morbidity of Diabetic Macular Oedema and Macular Oedema Secondary to Retinal Vein Occlusion

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Intravitreal Bevacizumab for Macular Oedema Secondary to Branch Retinal Vein Occlusion: More Data Required

Eye
MedicineArtsSensory SystemsOphthalmologyHumanities
2009English

Extended Injection Intervals After Switching From Ranibizumab to Aflibercept in Macular Edema Due to Central Retinal Vein Occlusion

Journal of Ophthalmology
Ophthalmology
2018English

Ranibizumab for Macular Edema Secondary to Retinal Vein Occlusion: A Meta-Analysis of Dose Effects and Comparison With No Anti-Vegf Treatment

BMC Ophthalmology
MedicineOphthalmology
2015English

One-Year Treatment Outcomes of Ziv-Aflibercept for Treatment-Naïve Macular Oedema in Branch Retinal Vein Occlusion

Acta Ophthalmologica
MedicineOphthalmology
2017English

Intravitreal PRN Ranibizumab Treatment for Macular Edemadue to Branch Retinal Vein Occlusion

Turkish Journal of Medical Sciences
Medicine
2017English

Anti-Vegf Therapy in Central Retinal Vein Occlusions

International Journal of Retina
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy